Cytokines and growth factors in the regulation of bone remodeling.
Osteoporosis and periodontal disease both represent examples of abnormal bone remodeling. As knowledge of the cellular and molecular events in the normal bone remodeling process has accumulated in the last decade, better understanding of the pathophysiology of bone loss associated with periodontal disease and with aging has occurred. This short review does not attempt to include all aspects of this topic but covers specific areas in which there have been recent advances. (1) Observations made in the last few years have indicated that a hierarchy of both receptor and nonreceptor tyrosine kinases may be involved in normal osteoclastic bone resorption and that certain members of these tyrosine kinase families may mediate cytokine effects. Studies in the op/op variant of murine osteopetrosis have shown that normal production of monocyte-macrophage colony-stimulating factor 1 (M-CSF, also called CSF-1) and activation of its receptor (the receptor tyrosine kinase c-fms) are required for normal osteoclast formation. (2) Studies in mice made deficient in nonreceptor tyrosine kinase by gene knockout have shown that expression of this nonreceptor tyrosine kinase is required for normal osteoclast action and ruffled border formation, although not for osteoclast formation. (3) Recent studies have shown that in addition to prostaglandins of the E series, other arachidonic acid metabolites may be involved in normal and abnormal osteoclastic bone resorption. 5-Lipoxygenase metabolites, the leukotrienes, stimulate isolated osteoclasts to form resorption pits as well as cause osteoclastic bone resorption in organ cultures of neonatal mouse calvariae. These compounds, which are unstable in tissue culture media, are readily inhibitable by agents that inhibit 5-lipoxygenase enzymes.(ABSTRACT TRUNCATED AT 250 WORDS)
Mundy
G R
GR
Division of Endocrinology and Metabolism, University of Texas Health Science Center, San Antonio.
D000375:Aging / Q000473:pathology; D000818:Animals; D016723:Bone Remodeling / Q000187:drug effects / Q000235:genetics / Q000502:physiology*; D001862:Bone Resorption / Q000503:physiopathology; D002455:Cell Division / Q000187:drug effects; D016207:Cytokines / Q000494:pharmacology / Q000502:physiology*; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology*; D006801:Humans; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects / Q000502:physiology; D010022:Osteopetrosis / Q000209:etiology / Q000235:genetics; D010024:Osteoporosis / Q000209:etiology / Q000235:genetics; D016392:Proto-Oncogene Proteins pp60(c-src) / Q000235:genetics / Q000494:pharmacology / Q000502:physiology
D016207:Cytokines; D006133:Growth Substances; D016392:Proto-Oncogene Proteins pp60(c-src)